On September 18, 2019 OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS), reported the appointment of Robert Petit, Ph.D., as its Chief Medical and Scientific Advisor. He is continuing to support the technology that he helped to develop at Advaxis (Press release, OS Therapies, SEP 18, 2019, View Source [SID1234539627]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Petit is a highly successful C-level executive and biopharma leader with a diverse background in research and development with over 25 years of experience in clinical development, and pre-clinical and translational research. In addition, he has helped to build, grow and secure investments for respected academic organizations, as well as private and publicly traded biopharma companies. An accomplished immuno-oncology scientist, innovator and drug developer, he has been integral to 7 NDA/BLA/EMA filings in the immuno-oncology space and was part of team at BMS who established the first checkpoint inhibitor therapy. Most recently, Dr. Petit served as Chief Scientific Officer of Advaxis, Inc., contributing to their successful NASDAQ IPO, raising significant capital, and evolving their platform technology to leverage both personal and shared neoantigens.
"I am excited to join the OS Therapies team and contribute toward realizing the potential of the OS Therapies lead program in the treatment of osteosarcoma," said Dr. Petit. "I also look forward to furthering the mission of OS Therapies by assisting in building a pipeline of assets that will improve treatment options and outcomes for patients with osteosarcoma."
"From our first meeting with Advaxis to discuss out-licensing for the Osteosarcoma indication, we knew Robert was the driving force behind the development of the technology," said Paul Romness, Chief Executive Officer of OS Therapies. "Already, he has been a crucial contributor to our team in bringing knowledge and passion for the technology. As our Chief Medical and Scientific Advisor, he is set to bring even more confidence and institutional knowledge to our investors and clinical researchers alike."